Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth R Plimack

Showing results (21-30 of 209) with videos related to

Pageof 21
Sort By:
Oncology (Williston Park, N.Y.)|November 19, 2014
Mechanisms of immunotherapy resistance in mCRPC: identifying the enemy on the visceral metastatic battlefieldJoseph W Kim, Marijo Bilusic, Elizabeth R Plimack
Leukemia & Lymphoma|August 19, 2007
Decitabine and its role in the treatment of hematopoietic malignanciesElizabeth R Plimack, Hagop M Kantarjian, Jean-Pierre Issa
European Urology|August 25, 2014
Corticosteroids and prostate cancer: friend or foe?Daniel M Geynisman, Russell Z Szmulewitz, Elizabeth R Plimack
Urologic Oncology|November 6, 2016
Circulating biomarkers to guide systemic therapy for urothelial carcinomaPhilip H Abbosh, Jonathan E Rosenberg, Elizabeth R Plimack
Current Oncology Reports|October 17, 2015
Targeting Signaling Transduction Pathways in Bladder CancerPhillip H Abbosh, David J McConkey, Elizabeth R Plimack
Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2013
Optimizing systemic therapy for bladder cancerSumanta K Pal, Matthew I Milowsky, Elizabeth R Plimack
European Urology|June 28, 2015
Osteoclast inhibitors in advanced prostate cancer: does the benefit extend beyond skeletal-related events?Daniel M Geynisman, Eric A Ross, Elizabeth R Plimack
Future Oncology (London, England)|February 18, 2016
Fox Chase Cancer Center's Genitourinary Division: a national resource for research, innovation and patient careRobert G Uzzo, Eric M Horwitz, Elizabeth R Plimack
Immunotherapy|June 29, 2016
Checkpoint inhibitors for renal cell carcinoma: current landscape and future directionsMatthew Zibelman, Pooja Ghatalia, Daniel M Geynisman, et al.
European Urology Focus|May 20, 2019
First-line Immunotherapy in Metastatic Urothelial CarcinomaPooja Ghatalia, Matthew Zibelman, Daniel M Geynisman, et al.
Pageof 21

Showing results (21-30 of 209) with videos related to

Sort By:
Pageof 21
Oncology (Williston Park, N.Y.)|November 19, 2014
Mechanisms of immunotherapy resistance in mCRPC: identifying the enemy on the visceral metastatic battlefieldJoseph W Kim, Marijo Bilusic, Elizabeth R Plimack
Leukemia & Lymphoma|August 19, 2007
Decitabine and its role in the treatment of hematopoietic malignanciesElizabeth R Plimack, Hagop M Kantarjian, Jean-Pierre Issa
European Urology|August 25, 2014
Corticosteroids and prostate cancer: friend or foe?Daniel M Geynisman, Russell Z Szmulewitz, Elizabeth R Plimack
Urologic Oncology|November 6, 2016
Circulating biomarkers to guide systemic therapy for urothelial carcinomaPhilip H Abbosh, Jonathan E Rosenberg, Elizabeth R Plimack
Current Oncology Reports|October 17, 2015
Targeting Signaling Transduction Pathways in Bladder CancerPhillip H Abbosh, David J McConkey, Elizabeth R Plimack
Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2013
Optimizing systemic therapy for bladder cancerSumanta K Pal, Matthew I Milowsky, Elizabeth R Plimack
European Urology|June 28, 2015
Osteoclast inhibitors in advanced prostate cancer: does the benefit extend beyond skeletal-related events?Daniel M Geynisman, Eric A Ross, Elizabeth R Plimack
Future Oncology (London, England)|February 18, 2016
Fox Chase Cancer Center's Genitourinary Division: a national resource for research, innovation and patient careRobert G Uzzo, Eric M Horwitz, Elizabeth R Plimack
Immunotherapy|June 29, 2016
Checkpoint inhibitors for renal cell carcinoma: current landscape and future directionsMatthew Zibelman, Pooja Ghatalia, Daniel M Geynisman, et al.
European Urology Focus|May 20, 2019
First-line Immunotherapy in Metastatic Urothelial CarcinomaPooja Ghatalia, Matthew Zibelman, Daniel M Geynisman, et al.
Pageof 21